オプションチェーンは、Lexeo Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Lexeo Therapeuticsの市場センチメントを評価します。.

Lexeo Therapeutics (NASDAQ:LXEO) 株価情報, オプションチェーン

LEXEO THERAPEUTICS INC

Lexeo Therapeutics

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Lexeo Therapeutics Inc

As of March 31, 2025, AL's fleet was comprised of 487 owned aircraft and 57 managed aircraft, with 255 new aircraft on order from Airbus and Boeing set to deliver through 2029.
Aircraft Investments
<ul>
<li>Delivered 14 new aircraft from AL's orderbook including four Airbus A220s, eight Boeing 737-8s, one Boeing 737-9, and one Boeing 787-10.</li>
<li>Aircraft investments totaled approximately $800 million, with the majority occurring in the second half of the quarter.</li>
</ul>
Sales
<ul>
<li>Sold 16 aircraft to third-party buyers.</li>
<li>Aircraft sales proceeds for the quarter totaled approximately $520 million.</li>
</ul>
Russia Fleet Insurance Settlements
<ul>
<li>Received an aggregate of $328.5 million in cash insurance settlement proceeds in the first quarter of 2025.</li>
</ul>

News

Air Lease Updates Q1 2025 Activity: Delivers 14 New Aircraft, Sells 16, And Receives $328.5M In Insurance Settlements

Ryan Hanley will bring its extensive local knowledge, relationships, and technical expertise to Stantec, particularly around the Irish water sector. The firm delivers a broad range of services, creating solutions for local authorities, government departments, private clients, utility companies, and other influential organizations. The acquisition is an important part of Stantec's goal of expanding its presence in Ireland.

Stantec Acquires Ryan Hanley To Expand Presence In Ireland's Water Sector; Deal Terms Not Disclosed

Guidance

RPM International Sees Q4 Sales To be Flat & Adjusted EBIT Of Low-Single-Digit Percentage Range

HC Wainwright &amp; Co. analyst Amit Dayal reiterates BioHarvest Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) with a Buy and maintains $14 price target.

Price Target

Reiteration

Analyst Ratings

BHST

HC Wainwright & Co. Reiterates Buy on BioHarvest Sciences, Maintains $14 Price Target

<a href="https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure" title="https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure">https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure</a>

Insider Trades

Bloomberg Reported Monday, CVS Health Is Facing Activist Investor

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and lowers the price target from $25 to $22.

LXEO

Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $22

RPM International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.49 by 28.57 percent. This is a 32.69 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $1.48 billion which missed the analyst consensus estimate of $1.51 billion by 2.00 percent. This is a 3.05 percent decrease over sales of $1.52 billion the same period last year.

Earnings

Earnings Misses

RPM International Q3 2025 Adj EPS $0.35 Misses $0.49 Estimate, Sales $1.48B Miss $1.51B Estimate

CVS Expects Financial Results To Meet Or Exceed FY25 Guidance

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and lowers the price target from $23 to $19.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Lowers Price Target to $19

Needham analyst Mike Matson reiterates ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) from Hold to Hold.

ICUI

Needham Reiterates Hold on ICU Medicalto Hold

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $66 price target.

RYTM

Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $66 Price Target

Andrew Beal, the billionaire founder and owner of Beal Financial Corporation, has publicly supported President Donald Trump&#8216;s contentious tariff policies, despite the resulting upheaval in the financial markets.
What Happened: Beal, in an exclusive interview with <a href="https://www.marketwatch.com/story/americas-richest-banker-says-trump-is-on-the-right-track-with-shock-and-awe-tariffs-e34bbae1">MarketWatch</a> on Monday, defended Trump&#8217;s "shock and awe" tariffs as essential for promoting free and equitable trade and for redefining the U.S.&#8217;s position in the global economy. He encouraged Trump to ignore requests for a tariff suspension from individuals such as billionaire hedge-fund manager Bill Ackman.
"Bill Ackman is wrong. We don't need another moratorium for 90 days," stated Beal and urged to seize the opportunity now.
Beal criticized the Federal Reserve&#8217;s monetary policies and the government&#8217;s deficit spending, asserting they have concealed the actual condition of the U.S. economy. He claimed that the real economy&#8217;s GDP has been contracting, while the reported GDP growth is primarily due to government spending.
The banker further contended that the U.S.&#8217;s trade deficit and fiscal deficit are untenable and must be addressed immediately to prevent long-term economic distress. Beal recognized the immediate effect of high tariffs on financial markets but maintained that there is no other feasible route forward.
SEE ALSO: <a href="https://benzinga.com/news/global/25/04/44679330/will-trump-impose-higher-tariffs-on-china-crypto-bettors-now-see-an-80-possibility" target="_blank" rel="noreferrer noopener">Will Trump Impose Higher Tariffs On China? Crypto Bettors Now See An 80% Possibility</a>
Why It Matters: Beal, a staunch supporter of Trump, has donated approximately $5 million to Trump&#8217;s presidential campaigns. Despite this, he has seldom publicly discussed his political leanings. He felt the need to express his support for Trump&#8217;s policies because of the growing public backlash over their effect on financial markets.
Beal&#8217;s endorsement comes at a time when other financial figures have expressed concern over Trump&#8217;s tariff policies. <a href="https://www.benzinga.com/25/04/44659521/bill-ackman-warns-against-launching-economic-nuclear-war-wants-a-90-day-time-out-on-trump-tariffs">Bill Ackman</a> warned of the potential economic repercussions of escalating tariffs, stating that business relies heavily on trust and confidence. Ackman also called for a 90-day pause on tariff implementation. Similarly, <a href="https://www.benzinga.com/25/04/44665530/jamie-dimon-once-a-tariff-supporter-warns-trumps-new-policy-could-slow-us-growth-fuel-inflation-the-quicker-the-issue-is-resolved-the-better">Jamie Dimon</a>, CEO of JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), cautioned that the tariffs could trigger inflation and slow the U.S. economy. Beal&#8217;s public support for Trump&#8217;s tariffs, despite these warnings, underscores the divisive nature of the policy.
<ul>
<li>READ MORE: <a href="https://benzinga.com/news/25/04/44678849/north-korean-it-workers-impersonating-americans-to-land-jobs-at-fortune-500-companies-to-fund-kim-jong-uns-weapons-program-report" target="_blank" rel="noreferrer noopener">North Korean IT Workers Impersonating Americans To Land Jobs At Fortune 500 Companies To Fund Kim Jong Un&#8217;s Weapons Program: Report &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Billionaire Banker Backs Trump's 'Shock And Awe' Tariff Policies, Slams Bill Ackman's Call For 90-Day Pause

General

RTX's Collins Aerospace Introduces Enhancements To SelfServ Platform An Integrated Common Use Self Service (CUSS) Solution

Legendary hedge fund manager Seth Klarman credits a counterintuitive lesson from Warren Buffett for shaping his investment success — a lesson that runs counter to the usual "spread your bets" mantra.
What Happened: In 2015, Klarman, who oversees the $30 billion Baupost Group, <a href="https://www.ft.com/content/6ab48700-a898-11e4-ad01-00144feab7de">told</a> the Financial Times that Buffett's "punch card" philosophy — treating investments as if you only have 20 slots for your entire life — transformed how he balances risk and reward. This approach encourages a tighter focus on quality businesses, rather than trying to hedge every possible angle.
&#8220;There is no need to overly diversify. Invest like you have a single, lifetime "punch card" with only 20 punches, so make each one count. Look broadly for opportunity, which can be found globally and in unexpected industries and structures,&#8221; wrote Klarman.
Buffett's stance challenges conventional wisdom, which often urges investors to diversify widely to reduce danger. According to him, excessive diversification merely protects against ignorance. In other words, if you know what you're doing, you don't need to own every stock under the sun. Instead, zero in on companies that boast "<a href="https://www.benzinga.com/general/11/06/1164308/build-a-wealthy-portfolio-with-these-economic-moats">economic moats</a>" — lasting advantages that can fend off rivals. That could mean a patented technology, strong brand loyalty, or a market where competition is scarce.
See also: <a href="https://in.benzinga.com/markets/25/03/44533852/what-would-buffett-do-with-markets-inches-away-from-the-extreme-fear-zone-is-it-finally-time-to-be-greedy">Warren Buffett Said &#8216;Be Fearful When Others Are Greedy, And Greedy When Others Are Fearful:&#8217; Does The Billionaire Investor&#8217;s Advice Hold Today As Markets Near The &#8216;Extreme Fear&#8217; Zone?</a>
Why It Matters: Still, neither Buffett nor Klarman advocate throwing caution to the wind. Strategic diversification remains a key defense, especially during bear markets. In such downturns, balancing select international stocks, short-term bonds, and some longer-term fixed-income assets can insulate a portfolio. This approach guards against severe losses, while preserving room to pounce on undervalued opportunities.
In practice, Klarman's track record shows how a leaner selection of investments can outperform a scattershot portfolio. By concentrating his capital in high-confidence ideas, he avoids the "diworsification" trap, a phrase <a href="https://www.cnbc.com/2023/11/29/charlie-munger-quotes-that-will-make-you-a-better-investor.html#:~:text=%22I%20think%20it's%20much%20easier,think%20I%20have%20an%20advantage.%22">coined</a> by Charlie Munger, that can dilute gains and mask pitfalls. And when the market stumbles, he relies on his carefully chosen buffer of diverse assets to steady returns. It's a disciplined two-step: identify great businesses worth backing for the long haul, and then round out those positions with strategic options for turbulent times.
For investors watching a twitchy market, the takeaway seems simple: big wins come from knowing what you own and why you own it, not from chasing every stock in sight. Buffett's "punch card" credo, as adopted by Klarman, suggests that sometimes the best strategy is finding a few gems — and hanging on tight.
Cover Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/04/44679339/howard-g-buffett-commits-1-billion-aid-to-ukraine-amidst-political-tensions">Warren Buffett&#8217;s Son Vows $1 Billion In Aid To Ukraine Amid Shifting US-Ukraine Ties Under Trump: &#8216;There&#8217;s No Easy Way To End The War&#8217;</a>

Personal Finance

Seth Klarman Learnt Warren Buffett's 'Lifetime Punch Card' Secret Long Ago — And It Helped Him Consistently Outperform The Market

Stocks and cryptocurrencies have been punched hard amid fears of economic fallout from President Donald Trump&#8217;s sweeping tariff measures.
Even so, Bitcoin, the world's largest cryptocurrency by market capitalization, has fared better than some of Wall Street&#8217;s tech behemoths.
What happened: The apex cryptocurrency has shed 15.79% of its value year-to-date, wiping out nearly $280 billion in investor wealth.&nbsp;
However, BTC was in a better position when compared with the "Magnificent 7" group, a cohort of seven large-cap technology companies.&nbsp;
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/04/44677895/another-crypto-firm-set-to-go-public-galaxy-digital-foresees-nasdaq-listing-soon-after-sec-approves-delaware-move">Another Crypto Firm Set To Go Public: Galaxy Digital Foresees Nasdaq Listing Soon After SEC Approves Delaware Move</a>
As evident, Nvidia, Tesla, Google's parent company Alphabet, Apple, and Amazon have all reported losses of over 20% since 2025 began. Elon Musk-led electric vehicle maker Tesla was the worst performer, plunging over 40% in the period.
Microsoft matched Bitcoin's decline, plunging 15.90% year-to-date, while Facebook's parent, Meta, posted smaller losses than the leading cryptocurrency.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Asset</td>
<td>YTD Losses&nbsp;</td>
<td>Price (Recorded at 4:50 a.m. ET)</td>
</tr>
<tr>
<td>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>40.20%</td>
<td>$233.29</td>
</tr>
<tr>
<td>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>28.21%</td>
<td>$97.64</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>27.10%</td>
<td>$181.46</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</td>
<td>22.06%</td>
<td>$146.75</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>21.06%</td>
<td>$175.26</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>15.90%</td>
<td>$357.86</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>15.79%</td>
<td>$79,102.14</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>12.46%</td>
<td>$516.25</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, the Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), which offers equal weight exposure to the "Mag 7" stocks, slumped 23.80% year-to-date. 
Interestingly, Bitcoin has strengthened against the &#8220;Mag 7&#8221; entities since October 2024, with the BTC to MAGS ratio jumping to its highest value in more than a year.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08052928/Screenshot-2025-04-08-145909-1024x536.png" alt="" class="wp-image-861537" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08052928/Screenshot-2025-04-08-145909-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08052928/Screenshot-2025-04-08-145909-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08052928/Screenshot-2025-04-08-145909-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08052928/Screenshot-2025-04-08-145909-1536x804.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08052928/Screenshot-2025-04-08-145909.png 1622w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Source: Trading View</figcaption></figure>
Price Action:&nbsp; At the time of writing, BTC was exchanging hands at $78,866.55, up 3.30% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Shares of MAGS were up 1.59% in pre-market trading after closing 0.27% higher at $41.47 during Monday&#8217;s regular session.
As of this writing, the stock&#8217;s momentum score was moderate at 65.16. To find ETFs with a much higher momentum, go to <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44677671/does-the-us-government-know-who-is-satoshi-nakamoto-crypto-lawyer-sues-department-of-homeland-security-to-unravel-bitcoin-creators-identity">Crypto Attorney Sues US Government To Unmask Satoshi Nakamoto, Creator Of Bitcoin</a></li>
</ul>
Photo: Bukhta Yurii/Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

AAPL

AMZN

GOOGL

MAGS

MSFT

NVDA

TSLA

Despite Tariff Turmoil, Bitcoin Outperforms 'Magnificent 7' Stocks In 2025 — Records Smaller Losses Than Nvidia, Tesla, Apple

Health Care

KALV

KalVista Pharmaceuticals Has Licensed Commercialization Rights Of Sebetralstat Investigational, Oral On-Demand Treatment For Hereditary Angioedema (HAE) To Kaken Pharmaceutical In Japan

Financial expert Suze Orman took to Facebook to address growing investor anxiety amid a turbulent week marked by geopolitical tensions and escalating trade policies. Orman&#8217;s message attempted to strike a balance between acknowledging real risks and fear while committing to a disciplined strategy, offering a roadmap for navigating what she called &#8220;2022-style volatility.&#8221;
What Happened: Orman <a href="https://www.facebook.com/suzeorman/posts/pfbid02BPqLXwNG57yTgaQr1dQuCBSbKWZWxJnf2UiTBz66Bn1sKyAWhHE2Jq1YwKXNLFVml/">highlighted</a> several bright spots for investors willing to look beyond headline panic. She noted the 10-year Treasury yield's drop to 3.8%, which could ease mortgage rates for prospective homebuyers. Bondholders, she added, might see portfolios stabilize as yields compress, providing rare fixed-income relief after years of rate hikes.
Her most emphatic recommendation focused on <a href="https://www.benzinga.com/money/best-credit-unions">Alliant Credit Union's</a> CDs, offering 4.25%-4.30% APY for 12-17 months. &#8220;That rate is incredible — don't miss it,&#8221; she warned, framing them as a safe harbor amid equity swings. Orman also pointed to gold's surge past $3,150/ounce and crude oil's breakdown below $65/barrel as signals of shifting capital flows, suggesting diversified portfolios could leverage these moves.
See also: <a href="https://in.benzinga.com/media/25/04/44679666/apple-customers-flock-to-stores-as-tariffs-threaten-to-drive-iphone-prices-up-by-45-report">Apple Customers Flock To Stores As Tariffs Threaten To Drive iPhone Prices Up By 45%: Report</a>
<h4 class="wp-block-heading">&#8216;Metrics Over Emotion&#8217;</h4>
Central to Orman's advice was monitoring the CBOE Volatility Index (VIX), <a href="https://in.benzinga.com/25/04/44678610/volatility-gauge-vix-spikes-118-in-3-days-tops-45-for-2nd-day-first-time-since-gfc-and-pandemic">which spiked above 45</a> — a level not seen since August 2024. &#8220;When the VIX is this high, it means fear is overwhelming logic,&#8221; she writes, emphasizing that similar VIX peaks historically preceded market rebounds. This metric, combined with disciplined dollar-cost averaging using &#8220;seriously tiny amounts,&#8221; forms her core defensive strategy.
Why It Matters: The fear among people that Orman refers to in her post stems largely from <a href="https://in.benzinga.com/news/global/25/04/44620889/trumps-liberation-day-tariffs-roil-markets-as-china-slams-typical-unilateral-bullying-asian-markets-plunge">Trump's fresh tariffs</a> on Chinese imports, enacted April 2 as part of his "Liberation Day" reset of American trade policy. Orman specifically cited China's retaliatory measures as the immediate trigger for the April selloff, creating a mix of trade friction and AI sector fears. However, in a <a href="https://www.youtube.com/watch?v=TNCHtqNWsgw">video</a> on her YouTube channel, she urges investors to distinguish between transient headlines and durable holdings, singling out AT&amp;T and Verizon as dividend stocks providing portfolio stability.
Reiterating a cornerstone of her philosophy, Orman also stressed that &#8220;money needed within five years doesn't belong in stocks&#8221;. For those adhering to retirement contributions, she advised unwavering consistency: &#8220;If you are contributing to a retirement account, do not stop. Stay the course. Keep investing steadily. That consistency is your power.&#8221;
Image via Shutterstock
Read next: <a href="https://in.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">Wall Street Eyes Recovery As S&amp;P 500, Nasdaq Futures Rise After Trump&#8217;s Tariff-Driven Selloff Wipes Out $9 Trillion In Six Weeks</a>

Equities

Bonds

Financing

Suze Orman Advises 'Calm' To Those 'Afraid Of What's Happening' In The Market: Here's Her Game Plan To Tackle 2022-Style Volatility

The Supreme Court on Monday allowed President Donald Trump to enforce the centuries-old Alien Enemies Act, enabling faster deportations of suspected gang members. The unsigned order grants Trump broad authority to invoke the 1798 law while litigation continues in lower courts.
What Happened: Originally intended for wartime emergencies, the law's use has sparked intense debate over presidential power. According to a CNN <a href="https://edition.cnn.com/2025/04/07/politics/supreme-court-deportation-flights-trump/index.html">report</a>, three liberal justices dissented, and Justice Amy Coney Barrett partially dissented. Still, the ruling preserves some safeguards by requiring that deportees receive formal notice and a chance for judicial review.
Trump celebrated the decision on Truth Social, calling it "a great day for justice in America." Attorney General Pam Bondi and Homeland Security Secretary Kristi Noem praised the outcome, arguing that it reaffirms a president's right to protect national security.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">BREAKING: The Supreme Court sides with the Trump Administration on the Alien Enemies Act. Tonight's decision is a landmark victory for the rule of law. An activist judge in Washington, DC does not have the jurisdiction to seize control of President Trump's authority to conduct…
&mdash; Attorney General Pamela Bondi (@AGPamBondi) <a href="https://twitter.com/AGPamBondi/status/1909380071162626527?ref_src=twsrc%5Etfw">April 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">President Trump was proven RIGHT once again! SCOTUS confirms our Commander-in-Chief Donald J. Trump has the power to stop the invasion of our country by terrorists using war time powers. LEAVE NOW or we will arrest you, lock you up and deport you. <a href="https://t.co/irLTSEo0GF">pic.twitter.com/irLTSEo0GF</a>
&mdash; Secretary Kristi Noem (@Sec_Noem) <a href="https://twitter.com/Sec_Noem/status/1909384333263298865?ref_src=twsrc%5Etfw">April 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See also: <a href="https://www.benzinga.com/personal-finance/25/04/44661713/a-beautiful-word-why-trump-insists-on-tariffs-as-essential-in-his-bid-to-save-american-manufacturing">&#8216;A Beautiful Word&#8217;: Why Trump Insists On Tariffs As Essential In His Bid To Save American Manufacturing</a>
Critics, including Justice Sonia Sotomayor, say the government's rush to remove migrants "poses an extraordinary threat to the rule of law." She pointed to an ongoing proceeding before US District Judge James Boasberg, who is deciding whether administration officials <a href="https://in.benzinga.com/25/03/44428767/trump-administration-failed-to-respond-to-court-order-on-deportation-flights-explain-non-compliance-by-tuesday-says-judge">disobeyed an earlier order</a> by continuing deportation flights.
Justice Ketanji Brown Jackson also voiced alarm, criticizing the court's reliance on the emergency docket and likening the moment to the infamous Korematsu ruling that allowed Japanese American internment during World War II.
Why It Matters: The Trump administration asserts that an influx of Venezuelan gang members amounts to an "invasion," justifying the use of the Alien Enemies Act. Opponents argue such rapid deportations risk errors — like the mistaken removal of a Maryland father under a different policy — while leaving migrants with little time to seek legal relief.
By granting Trump's request, the Supreme Court effectively suspends Boasberg's orders blocking the law's use, setting the stage for more legal battles ahead.
Despite the controversy, a <a href="https://in.benzinga.com/news/25/02/43769836/trump-gains-trust-of-majority-on-americans-on-immigration-and-economy" target="_blank" rel="noreferrer noopener">recent poll</a> indicates that 52% of Americans trust Trump&#8217;s handling of immigration. This trust is particularly strong among Republicans, with 87% expressing confidence in his immigration policies. However, the administration's approach to deportations and its legal challenges could impact public perception and policy implementation.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/news/management/25/04/44676213/trumps-tariffs-are-impacting-main-street-not-just-wall-street-blackrock-ceo-larry-fink-says">Trump&#8217;s Tariffs Are &#8216;Impacting Main Street,&#8217; Not Just Wall Street: BlackRock CEO Larry Fink Says</a>

Government

Politics

Alien Enemies Act Survives Court Challenge — Trump Gains Green Light For Swift Deportations

Contracts

Telix Pharmaceuticals Has Selected Cardinal Health As One Of Its Commercial Radiopharmaceutical Distributors To Supply Finished Unit Doses Of Gozellix, PSMA-PET Imaging Agent For Prostate Cancer In US

CVS Health Names Brian Newman As Executive Vice President And Chief Financial Officer Designate Effective April 21

Press Releases

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Management

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Comments

Lexeo Therapeutics

Lexeo Therapeutics (LXEO) オプション

Lexeo Therapeutics (NASDAQ:LXEO) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル